扩展静脉血栓栓塞预防对胰腺切除术后VTE和PPH的影响
该单中心回顾性分析纳入2004-2021年因恶性肿瘤行胰腺切除术的478例患者,比较接受与未接受依诺肝素扩展VTE预防者的出院后VTE和PPH发生率。结果显示扩展预防与出院后VTE(2.3% vs 2.8%,P=0.99)及PPH(3.4% vs 1.9%,P=0.43)均无显著关联,提示扩展预防安全但可能并非所有患者必需。
要点
- 胰腺癌术后扩展VTE预防未显著降低出院后VTE发生率。
- 扩展预防未增加出院后PPH风险,包括使用抗血小板药者。
- 扩展VTE预防安全,但可能无需用于所有胰腺切除患者。
核心结论
- 胰腺恶性肿瘤切除术后扩展VTE预防与出院后VTE和PPH发生率差异无关。
- 数据提示扩展VTE预防安全,但可能并非所有患者必需。
研究设计与样本
- 单机构回顾性分析2004-2021年因恶性肿瘤行胰腺切除术的患者,共478例。
- 比较接受与未接受依诺肝素扩展VTE预防者的出院后90天内VTE和PPH发生率。
主要发现
- 接受与未接受扩展预防者出院后VTE发生率分别为2.3%与2.8%(P=0.99)。
- 接受与未接受扩展预防者出院后PPH发生率分别为3.4%与1.9%(P=0.43)。
- 使用抗血小板药亚组中,加用依诺肝素与VTE(3.9% vs 0%,P=0.31)和PPH(3.0% vs 4.5%,P=0.64)发生率无关。
临床怎么用
- 胰腺切除术后可考虑扩展VTE预防,但需个体化评估,并非所有患者均需。
- 对使用抗血小板药的患者,加用依诺肝素未显示增加出血或VTE风险。
局限性
- 单中心回顾性设计可能限制结果外推。
- 样本量有限,亚组分析效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare rates of venous thromboembolism (VTE) and postpancreatectomy hemorrhage (PPH) in patients with pancreatic or periampullary malignancy preimplementation and postimplementation of routine extended VTE prophylaxis. BACKGROUND: Guidelines recommend up to 28 days of VTE prophylaxis following major abdominal cancer operations. There is a paucity of data examining rates of VTE and PPH in patients who receive extended VTE prophylaxis following pancreatectomy. METHODS: Single-institution analysis of patients who underwent pancreatectomy for malignancy (2004-2021). VTE and PPH rates within 90 days of discharge were compared based on receipt of extended VTE prophylaxis with enoxaparin. RESULTS: A total of 478 patients were included. Twenty-two (4.6%) patients developed a postoperative VTE, 12 (2.5%) of which occurred postdischarge. Twenty-five (5.2%) patients experienced PPH, 13 (2.7%) of which occurred postdischarge. There was no associated difference in the development of postdischarge VTE between patients who received extended VTE prophylaxis and those who did not (2.3% vs 2.8%, P =0.99). There was no associated difference in the rate of postdischarge PPH between patients who received extended VTE prophylaxis and those who did not (3.4% vs 1.9%, P =0.43). In the subset of patients on antiplatelet agents, the addition of enoxaparin did not appear to be associated with higher VTE (3.9 vs. 0%, P =0.31) or PPH (3.0 vs. 4.5%, P =0.64) rates. CONCLUSIONS: Extended VTE prophylaxis following pancreatectomy for malignancy was not associated with differences in postdischarge VTE and PPH rates. These data suggest extended VTE prophylaxis is safe but may not be necessary for all patients following pancreatectomy.
引用
- Stitzel HJ, Hue JJ, Elshami M, et al. Assessing the use of Extended Venous Thromboembolism Prophylaxis on the Rates of Venous Thromboembolism and Postpancreatectomy Hemorrhage Following Pancreatectomy for Malignancy. Ann Surg. 2022. PMID: 35797622. doi:10.1097/SLA.0000000000005483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。